Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.16% and ...

The European Medicines Agency (EMA) will allow Novo Nordisk to add risk reduction for events related to kidney disease to the ...

But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...

Initial research has focused on obesity, but Ozempic, Wegovy and Mounjaro may potentially be used for addiction, heart ...

Wegovy and other GLP-1 medications have become extremely popular over the past few years. Novo Nordisk (which makes both ...

Elon Musk, the richest person alive and the co-head of President-elect Donald Trump’s new Department of Government Efficiency ...

Eli Lilly ( LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug ...

The agency is due to make a determination on the shortage status of Zepbound by Dec. 19. But another delay could be possible ...

Progress in assessing cardiovascular risk and identifying early prevention opportunities, improvements in treating heart failure, new therapies for bleeding strokes, strategies for reducing the ...

They are currently approved for treating diabetes, obesity and those with a history of cardiovascular disease in people who ...

Technology companies continue to hold most of the top spots in the annual Management Top 250 ranking of America’s best-run ...

Despite this escalating demand for popular GLP-1 drugs, the prices for some of these products are actually dropping. Dr.